CA 15-3: Uses and limitation as a biomarker for breast cancer
作者： Michael J. Duffy , Denis Evoy , Enda W. McDermott
DOI: 10.1016/J.CCA.2010.08.039
关键词: Metastatic breast cancer 、 Localized disease 、 Oncology 、 Disease 、 Medicine 、 Physical examination 、 Internal medicine 、 Asymptomatic 、 Biomarker (medicine) 、 CA 15-3 、 Breast cancer
摘要: … the most widely used serum marker in patients with breast cancer. Its main use is for monitoring … In monitoring therapy in this setting, CA 15-3 should not be used alone but measured in …
lenus.ie
elsevier.com
sci-hub.se 参考文章(78)
Xavier Filella, Petra Stieber, Lori J. Sokoll, Dorothea Nagel, Herbert A. Fritsche, Frédéric Troalen, Daniel W. Chan, Terrie G. Gornet, Klaus Peisker, Torsten Hoff, Ralf Beyrau, Gerard J. Van Kamp, Wolfram Jäger, Jean M.G. Bonfrer, Ingrid Domke, Rafael Molina, Michael Untch, Clinical evaluation of the Elecsys CA 15-3 test in breast cancer patients. Clinical Laboratory. ,vol. 49, pp. 15- 24 ,(2003)
F Canizares, J Sola, M Perez, I Tovar, M De Las Heras, J Salinas, R Penafiel, P Martinez, None, Preoperative values of CA 15-3 and CEA as prognostic factors in breast cancer: a multivariate analysis. Tumor Biology. ,vol. 22, pp. 273- 281 ,(2001) , 10.1159/000050627
Joseph A. Mollick, Robert W. Carlson, Rational surveillance programs for early stage breast cancer patients after primary treatment. Breast disease. ,vol. 21, pp. 47- 54 ,(2004) , 10.3233/BD-2004-21107
Christine L Hattrup, Sandra J Gendler, MUC1 alters oncogenic events and transcription in human breast cancer cells Breast Cancer Research. ,vol. 8, pp. 1- 10 ,(2006) , 10.1186/BCR1515
M. Rosselli Del Turco, Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up JAMA: The Journal of the American Medical Association. ,vol. 271, pp. 1593- 1597 ,(1994) , 10.1001/JAMA.271.20.1593
Joy M. Burchell, Arron Mungul, Joyce Taylor-Papadimitriou, O-linked glycosylation in the mammary gland: changes that occur during malignancy. Journal of Mammary Gland Biology and Neoplasia. ,vol. 6, pp. 355- 364 ,(2001) , 10.1023/A:1011331809881
D W Chan, R A Beveridge, H Muss, H A Fritsche, G Hortobagyi, R Theriault, D Kiang, B J Kennedy, M Evelegh, Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease. Journal of Clinical Oncology. ,vol. 15, pp. 2322- 2328 ,(1997) , 10.1200/JCO.1997.15.6.2322
Andrea Nicolini, Gianna Tartarelli, Angelo Carpi, Maria Rita Metelli, Paola Ferrari, Loretta Anselmi, Massimo Conte, Piero Berti, Paolo Miccoli, Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases. BMC Cancer. ,vol. 6, pp. 269- 269 ,(2006) , 10.1186/1471-2407-6-269
Daniel F Hayes, Vincent R Zurawski Jr, Donald W Kufe, None, Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer. Journal of Clinical Oncology. ,vol. 4, pp. 1542- 1550 ,(1986) , 10.1200/JCO.1986.4.10.1542
Robert C. Bast, Peter Ravdin, Daniel F. Hayes, Susan Bates, Herbert Fritsche, John M. Jessup, Nancy Kemeny, Gershon Y. Locker, Robert G. Mennel, Mark R. Somerfield, 2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology* Journal of Clinical Oncology. ,vol. 19, pp. 1865- 1878 ,(2001) , 10.1200/JCO.2001.19.6.1865